Alshihmani Ahmed Hussein Hasan, Mahmoudi Mahmoud, Kheder Ramiar Kamal, Fadaee Afsane, Esmaeili Seyed-Alireza
Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Immunology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Immun Inflamm Dis. 2025 Jun;13(6):e70211. doi: 10.1002/iid3.70211.
Psoriasis is a chronic autoimmune skin condition that is increasingly prevalent globally, causing significant challenges for affected individuals. The disease is influenced by a combination of genetic factors, environmental triggers, immune system dysfunction, and its systemic nature with comorbidities like cardiovascular diseases and depression. Macrophages, essential immune cells, play a critical role in the pathogenesis of psoriasis, displaying various functions and activation states.
This study aims to investigate the impact of M2 macrophages on the progression and management of psoriasis, particularly their ability to support tissue healing and reduce inflammation.
M1 macrophages are involved in early inflammation and pro-inflammatory responses when activated by LPS and IFN-γ, while M2 macrophages are activated by IL-4 and IL-13 to promote anti-inflammatory and tissue repair processes. Imbalance in M1 and M2 polarization can worsen autoimmune conditions such as psoriasis, underscoring the need to regulate macrophage phenotypes for effective disease management. Recent research suggests that targeting M2 macrophages could be a promising therapeutic approach for treating psoriasis, especially through advanced biologic treatments such as anti-IL-17 and anti-IL-23 therapies. Enhancing the function of M2 macrophages has been shown to reduce inflammation and improve outcomes in psoriatic conditions, potentially lowering the risk of comorbidities through early intervention and personalized treatment. Biomarkers like CD163(+) M2 macrophages are associated with disease progression, while treatments that enhance M2 macrophage function, such as PSORI-CM02 and Treg-of-B cell therapies, show potential in alleviating psoriasis symptoms.
Understanding the crucial role of M2 macrophages in psoriasis could pave the way for innovative treatment approaches that regulate immune responses and enhance patient care. Further exploration of macrophage biology in psoriasis may provide fresh perspectives on personalized therapeutic options for managing psoriasis and other inflammatory skin conditions, ultimately improving patient care and quality of life for individuals with this chronic skin condition.
银屑病是一种慢性自身免疫性皮肤病，在全球范围内日益普遍，给患者带来了重大挑战。该疾病受遗传因素、环境诱因、免疫系统功能障碍及其全身性本质（伴有心血管疾病和抑郁症等合并症）的综合影响。巨噬细胞作为重要的免疫细胞，在银屑病的发病机制中发挥着关键作用，表现出多种功能和激活状态。
本研究旨在探讨M2巨噬细胞对银屑病进展和治疗的影响，特别是其支持组织愈合和减轻炎症的能力。
M1巨噬细胞在被脂多糖（LPS）和干扰素-γ（IFN-γ）激活时参与早期炎症和促炎反应，而M2巨噬细胞则被白细胞介素-4（IL-4）和白细胞介素-13激活，以促进抗炎和组织修复过程。M1和M2极化的失衡会使银屑病等自身免疫性疾病恶化，这突出了为有效治疗疾病而调节巨噬细胞表型的必要性。最近的研究表明，靶向M2巨噬细胞可能是治疗银屑病的一种有前景的治疗方法，特别是通过抗白细胞介素-17（anti-IL-17）和抗白细胞介素-23（anti-IL-23）疗法等先进的生物治疗手段。增强M2巨噬细胞的功能已被证明可以减轻银屑病的炎症并改善治疗效果，可能通过早期干预和个性化治疗降低合并症的风险。像CD163(+) M2巨噬细胞这样的生物标志物与疾病进展相关，而增强M2巨噬细胞功能的治疗方法，如PSORI-CM02和B细胞调节性T细胞（Treg-of-B cell）疗法，在减轻银屑病症状方面显示出潜力。
了解M2巨噬细胞在银屑病中的关键作用可为调节免疫反应和改善患者护理的创新治疗方法铺平道路。对银屑病中巨噬细胞生物学的进一步探索可能为管理银屑病和其他炎症性皮肤病的个性化治疗选择提供新的视角，最终改善患有这种慢性皮肤病的患者的护理和生活质量。
